Weekly IPO Review: X-Energy Prices, Pershing Tests the Tape

X-Energy gave the week its only clean handoff from filing work to public trading, and that mattered more than the usual pile of amendments. The company priced 44,254,659 shares at $23, above the $16 to $19 range in its April 20 S-1/A, raised about $1.02 billion, and then closed its April 24 debut at $29.20, up 27% from the offer price. In a market that has spent most of 2026 talking about reopening rather than actually reopening, that was the week’s best proof that investors will still stretch for size when the theme is hot enough and the book is strong enough.

X-Energy reset the tone

The deal worked because it hit several pressure points at once. X-Energy arrived with a large syndicate, a live AI-power narrative, and enough demand to move from a marketed range to an upsized print. The company said trading would begin on Nasdaq on April 24 and named J.P. Morgan, Morgan Stanley, Jefferies and Moelis as lead joint book-runners in the pricing release. That sequence matters for the rest of the calendar: after a slow first quarter, issuers now have at least one fresh comp showing that institutions will pay for an IPO that feels scarce, thematic and scaled.

Pershing still owned the week without pricing

Bill Ackman’s combined Pershing transaction remained the biggest story in the pipeline even though it still had not crossed into a completed deal by the end of the review window. The PSUS registration kept the public offering at $50 per share and, unusually, said buyers in the fund IPO would receive 20 shares of Pershing Square Inc. common stock for every 100 PSUS shares purchased, for no additional consideration. The same filing disclosed a concurrent private placement that, together with the manager’s own investment, represented $2.8 billion of aggregate proceeds. By Monday, April 27, Reuters reported the combined IPO was expected to raise about $5 billion. That is still a demand test, not a result, but it is the week’s clearest signal that the market is at least willing to engage with scale again.

The rest of the calendar finally put numbers on paper

Beneath those two names, the better signal was not volume but specificity. Lincoln International’s public S-1 put a recognizable advisory franchise into the open with Goldman Sachs and Morgan Stanley leading, but it stopped short of setting a range. Avalyn Pharma’s April 23 amendment set terms for 11.8 million shares at $16 to $18, and Fierce Biotech noted midpoint net proceeds of about $181.8 million to fund late-stage pulmonary-fibrosis work. SunScout filed publicly for a $22 million deal at $5 to $6 and shifted the listing venue to NYSE American, which looked more realistic than the earlier Nasdaq posture. Silver Bow Mining’s 8-A at least put listing mechanics in place for NYSE American, while GreenVector continued to amend a small Nasdaq deal without breaking out of the usual foreign small-cap pattern.

One effective name was not really an IPO read-through

AIR Holdings’ effectiveness notice was real progress, but it belongs in a different bucket. The filing cleared the way for AIR’s business combination with Cantor Equity Partners III and pointed to a May 12 shareholder vote for the combined company, AIR Global PLC. That may matter for merger completion and aftermarket supply, but it does not tell investors much about fresh IPO demand.

The week mattered because it finally produced a live benchmark. X-Energy showed that the market will still absorb a billion-dollar deal and reward it if the narrative, sponsorship and order book line up. Pershing now has to prove that appetite extends from one hot thematic issuer to a far more unusual structure. Everything else on the board still needs to convert term sheets and amendments into actual pricing.